display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
multiple myeloma - 2nd line (L2)
multiple myeloma - 2nd line (L2)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus pomalidomide and dexamethasone KEYNOTE-183

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons